An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy

被引:1
|
作者
Jiang, Wei [1 ,3 ]
Tie, Zuoxiu [3 ]
Yu, Chi [2 ]
Chen, Yu [4 ]
Liu, Dan [2 ]
Li, Bin [1 ]
机构
[1] Guangxi Univ Sci & Technol, Med Coll, Dept Biochem & Mol Biol, Liuzhou 545005, Peoples R China
[2] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Shenyang 110142, Peoples R China
[3] Nanjing Univ, Coll Engn & Appl Sci, MOE Key Lab High Performance Polymer Mat & Technol, Nanjing 210033, Peoples R China
[4] Commonwealth Sci & Ind Res Org CSIRO Mfg, Clayton, Vic 3168, Australia
关键词
Energy metabolism; Cell dormancy; Lysosome; Glutathione; Cisplatin prodrug; DRUG; POLYMER;
D O I
10.1016/j.biomaterials.2023.122354
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Although inhibiting the energy metabolism of tumor cells has become an effective measure to enhance chemotherapy, tumor cells can still escape the lethal effect of chemotherapy by entering a dormancy state with low-energy expenditure. Herein, the glutathione (GSH)-responsive nanoplatform (C-A-D NPs) were constructed to inhibit energy metabolism and lysosomal activity of tumor cells, thereby forcing tumor cells to remain vulnerable to cisplatin. In this system, cisplatin prodrug was reduced to cisplatin by GSH, and D-peptide and apoptozole (Az) were released to inhibit the energy metabolism and autophagy-lysosome pathway of tumor cells. The suppressed autophagy-lysosome pathway prevents tumor cells from entering a low-energy dormancy state, resulting in the loss of resistance to the lethal effect of cisplatin with high-energy expenditure and insufficient energy supply. Such engineered nanoplatform effectively enhances the chemotherapeutic effect of cisplatin by inhibiting intracellular energy metabolism and lysosomal activity, showing great clinical prospects.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy
    Abuzeid, Waleed M.
    Jiang, Xiaoling
    Shi, Guoli
    Wang, Hui
    Paulson, David
    Araki, Koji
    Jungreis, David
    Carney, James
    O'Malley, Bert W., Jr.
    Li, Daqing
    JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (07): : 1974 - 1985
  • [2] RESPONSE OF METASTASIZED SEX CORD GONADAL STROMAL TUMOR OF THE TESTIS TO CISPLATIN-BASED CHEMOTHERAPY
    DIECKMANN, KP
    LOY, V
    JOURNAL OF UROLOGY, 1994, 151 (04): : 1024 - 1026
  • [3] Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
    Chun, Jaemoo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [4] Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: Response to cisplatin-based chemotherapy
    Bar, JK
    Harlozinska, A
    Popiela, A
    Noga, L
    TUMOR BIOLOGY, 2001, 22 (02) : 83 - 91
  • [5] COMPARISON OF ANTIEMETIC ACTIVITY OF CHLOROPROMAZINE AND HIGH-DOSES OF METOCLOPRAMIDE IN CISPLATIN-BASED CHEMOTHERAPY
    TSAVARIS, NB
    PAPAIOANNOU, D
    BELDECOS, D
    KAKOLIRIS, S
    MYLONAKIS, N
    KARVOUNIS, N
    KOMITSOPOULOU, P
    KARAGIAOURIS, P
    SARMAS, J
    TZANNOU, I
    BACOYANNIS, C
    KOSMIDIS, P
    ACTA ONCOLOGICA, 1990, 29 (08) : 1005 - 1009
  • [6] CISPLATIN-BASED CHEMOTHERAPY IN ELDERLY LUNG CANCER PATIENTS: SAFETY AND ACTIVITY OF A FRACTIONATED SCHEDULE
    Pennucci, M. C.
    Del Freo, A.
    Della Seta, R.
    Iori, C.
    Mambrini, A.
    Manni, A.
    Muttini, M. P.
    Spinelli, I.
    Cantore, M.
    ANNALS OF ONCOLOGY, 2004, 15 : 28 - 28
  • [7] REDUCED NATURAL CYTOTOXIC-CELL ACTIVITY IN PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY AND IN MICE TREATED WITH CISPLATIN
    POWELL, CB
    MUTCH, DG
    KAO, MS
    COLLINS, JL
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1990, 79 (03): : 424 - 429
  • [8] Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy
    Zargar, Parisa
    Koochakkhani, Shabnaz
    Hassanzadeh, Marziyeh
    Taziani, Yaghoub Ashouri
    Nasrollahi, Hamid
    Eftekhar, Ebrahim
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (04) : 2755 - 2763
  • [9] Changes in circulating endothelial cells (CECs) during treatment with cisplatin-based chemotherapy for testicular cancer
    Altena, R.
    De Haas, E. C.
    Tibbe, A. G.
    Smit, A. J.
    van Roon, A.
    Meijer, C.
    Boezen, M. H.
    van der Meer, J.
    Sleijfer, D. T.
    Gietema, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy
    Parisa Zargar
    Shabnaz Koochakkhani
    Marziyeh Hassanzadeh
    Yaghoub Ashouri Taziani
    Hamid Nasrollahi
    Ebrahim Eftekhar
    Molecular Biology Reports, 2022, 49 : 2755 - 2763